gsk.com (GSK) - Quarterly EPS earnings growth

Corporate company logo of GSK plc (GSK)

Patent protection for vaccines and high R&D expenditures create a defensive moat that supports the current quarterly EPS growth rate, where the indicator reaches -23.50. GSK plc is implementing sustainable "green chemistry" and transitioning to safe propellants. Meanwhile, a portion of production and testing is outsourced to external CMOs, necessitating strict quality control.

gsk.com (GSK) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for GSK plc (GSK)

- share price and expert price forecast:
Stock Price gsk.com|GSK - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization GlaxoSmithKline plc|GSK - Company Buyout Price
- balance sheet net asset value indicators:
Net Assets per Single Share GSK|GSK - Accounting Capitalization|Market Capitalization to Book Value Ratio gsk.com|GSK - Company Balance Sheet Assets
- debt level and financial liquidity data:
Total Debt to Capital GSK plc|GSK - Long-Term Indebtedness to Equity|Short-Term Debt to Equity gsk.com|GSK - Company Total Debt Obligations|Debt to Book Capitalization Ratio GlaxoSmithKline plc|GSK - Company Long-Term Debts|Company Current Liabilities GSK|Quick Liquidity gsk.com
- earnings and market multiples details:
GSK - Profit After Tax|Expected Profit GSK plc|GSK - Price to Earnings Ratio|Forward P/E Multiple gsk.com|GSK - Price/Earnings to Growth Multiple|EV/EBITDA Multiple GlaxoSmithKline plc|GSK - Operating profit before depreciation charges|Earnings per share for the last twelve months GSK|GSK - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months gsk.com|GSK - Earnings growth in current year|Net earnings per share growth forecast for next year GSK plc
Analysis of all company metrics:GSK plc
Flagship merchandise of gsk.com

Investors are verifying the reliability of GSK plc (GSK) through the dynamics of earnings per share. This quarterly EPS gap measures net income growth rates, reflecting the efficiency of capital management. The positive trend confirms the viability of the operating model. For this defensive pharma holding, this indicator smooths out macroeconomic shocks, revealing only seasonal fluctuations in vaccine sales. Peak values of the metric signal a risk of price correction.

Competitor analysis

LLY: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ABBV|AZN (AstraZeneca AB) - Quarterly EPS earnings growth|Novartis Pharma (NVS) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Merck & Co., Inc. (MRK)|novonordisk.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth AMGN (Amgen)|Net earnings per share growth for the trailing year Pfizer Inc|Sanofi Aventis - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Bristol-Myers Squibb Co. (BMY)|Takeda Pharmaceutical (TAK) - Year-over-year earnings per share growth for the last twelve months|TEVA - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Dr. Reddy's|Quarterly EPS earnings growth Viatris Inc|Year-over-year net earnings per share growth for the last 12 months ROIV (Roivant Sciences Ltd)|ZLAB (Zai Lab Corp) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Bausch Health Companies BHC|COSM (cosmosholdingsinc.com) - Year-over-year net earnings per share trend for the last twelve months